phosphorylcholine and paromomycin

phosphorylcholine has been researched along with paromomycin in 60 studies

Research

Studies (60)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	16 (26.67)	29.6817
2010's	40 (66.67)	24.3611
2020's	4 (6.67)	2.80

Authors

Authors	Studies
Murray , HW	1
Sundar, S	1
Boelaert, M; Bryceson, AD; Croft, SL; Desjeux, P; Guerin, PJ; Olliaro, P; Sundar, S; Wasunna, MK	1
Carter, KC; Mullen, AB; Pereira, OC; Spickett, C; Sundar, S	1
Berman, J	2
Desjeux, P	1
Hepburn, NC	1
Murray, HW	2
Kumar, A; Sundar, S	1
Croft, SL; Seifert, K; Yardley, V	1
Minodier, P; Parola, P	1
Boucher, P; Hadighi, R; Khamesipour, A; Meamar, AR; Mohebali, M; Ouellette, M; Roy, G	1
Olliaro, P; Sundar, S	1
Darley, S; Laxminarayan, R; Olliaro, P; Sundar, S	1
Aguiar, MG; Fernandes, AP; Ferreira, LA; Nunan, EA; Nunan, FA; Silva, DL	1
Liarte, DB; Murta, SM	1
Barragán, P; López-Velez, R; Olmo, M; Podzamczer, D	1
Aguiar, MG; Fernandes, AP; Ferreira, LA; Pereira, AM	1
Balasegaram, M; Boelaert, M; Faiz, MA; Meheus, F; Olliaro, P; Rijal, S; Sundar, S	1
Gupta, S; Sane, SA; Shakya, N	1
Olliaro, PL	1
Alam, S; Arora, R; Balasegaram, M; Chakravarty, J; Das, P; Ellis, S; Kumari, P; Lal, CS; Modabber, F; Nawin, K; Olliaro, P; Pandey, K; Rai, M; Sharma, B; Sinha, PK; Strub-Wourgaft, N; Sundar, S; Vaillant, M; Verma, DK; Verma, N	1
Boelaert, M; van Griensven, J	1
Alvar, J; Arana, B; Battacharya, S; Das, P; Kroeger, A; Matlashewski, G; Mondal, D; Rijal, S; Sinha, PK; Sundar, S; Zilberstein, D	1
Leprohon, P; Moreira, W; Ouellette, M	1
Kumar, M; Singh, N; Singh, RK	1
Bhandari, V; Deep, DK; Dujardin, JC; Kulshrestha, A; Prajapati, VK; Ramesh, V; Salotra, P; Schonian, G; Stark, O; Sundar, S	1
Aguiar, MG; Carneiro, G; Fernandes, AP; Ferreira, LA	1
Das, P; Das, S; Pandey, K; Rabidas, VN; Rani, M; Sahoo, GC; Singh, D	1
Chakravarty, J; Sundar, S	1
Abebe, T; Hailu, A; Kassahun, A; Utaile, M	1
Agarwal, N; Arya, SC	1
Boulet, G; Cos, P; Delputte, P; Dujardin, JC; Hendrickx, S; Lachaud, L; Maes, L; Mondelaers, A; Rijal, S	1
Das, P; Das, S; Pandey, K; Rabidas, V; Rani, M; Sahoo, GC	1
Burden-Teh, E; Williams, HC; Wootton, CI	1
Cos, P; Delputte, P; Eberhardt, E; Hendrickx, S; Maes, L; Mondelaers, A	1
Aguiar, MG; de Morais-Teixeira, E; Ferreira, LA; Rabello, A; Soares de Souza Lima, B	1
Beyers, J; Cos, P; Delputte, P; Eberhardt, E; Hendrickx, S; Lachaud, L; Maes, L; Mondelaers, A	1
Ali, V; Bimal, S; Das, P; Das, VNR; Lal, CS; Murti, K; Pal, B; Pandey, K; Siddiqi, NA; Topno, RK; Verma, N; Verma, RB	1
Caljon, G; Cos, P; Delputte, P; Hendrickx, S; Mabille, D; Maes, L; Van den Kerkhof, M	1
Alvar, J; Alves, F; Balasegaram, M; Boer, MD; Ellis, S; Faiz, A; Goyal, V; Haque, R; Jamil, K; Rahman, R; Rijal, S; Samad, R; Sharma, B; Strub-Wourgaft, N	1
Croft, SL; Murdan, S; Van Bocxlaer, K; Wijnant, GJ; Yardley, V	1
Arrese Estrada, J; Cnops, L; Darcis, G; de Leval, L; Giot, JB; Hayette, MP; Leonard, P; Moutschen, M; Tassin, F; Van der Auwera, G	1
de Paula, E; Giorgio, S; Ortega, V	1
Fernando, SD; Rajapakse, S; Rodrigo, C; Weeratunga, P	1
Singh, A; Sundar, S	1
Aguado, B; Camacho, E; Castanys, S; Corvo, L; Dujardin, JC; Gamarro, F; García-Hernández, R; Imamura, H; Rastrojo, A; Requena, JM; Vargas, P	1
Ahuja, V; Ghosh, P; Haque, R; Hossain, AFMA; Hossain, MA; Hossain, MS; Kumar, A; Mahshin, M; Maruf, S; Mondal, D; Shamsuzzaman, AKM; Sharma, A; Sharma, V	1
Caljon, G; Cos, P; Delputte, P; Gielis, JF; Hendrickx, S; Maes, L; Van Bockstal, L; Van den Kerkhof, M	1
Alvar, J; Alves, F; Balasegaram, M; Bern, C; Burza, S; Das, P; Ellis, S; Goyal, V; Hightower, A; Lima, N; Mahajan, R; Pandey, K; Rabi Das, VN; Rijal, S; Sharma, B; Singh, RS; Singh, SN; Strub-Wourgaft, N; Sunyoto, T; Topno, RK	1
Alvar, J; Boelaert, M; Das, P; Mondal, D; Rijal, S; Sundar, S	1
Alsford, S; Baker, N; Collett, CF; Horn, D; Hutchinson, S; Kitson, C; Santrot, MV; Steele-Stallard, HB	1
Alvar, J; Alves, F; Bern, C; Burza, S; Das, P; Das, VNR; Goyal, V; Hightower, A; Lima, N; Pandey, K; Rijal, S; Singh, RS; Singh, SN; Strub-Wourgaft, N; Sunyoto, T	1
Bhattacharya, A; Bigot, S; Gingras, H; Leprohon, P; Mestdagh, A; Mukherjee, A; Ouellette, M; Padmanabhan, PK; Papadopoulou, B; Roy, G	1
Çavuş, İ; Harman, M; Kaya, T; Özbilgin, A; Yıldırım, A	1
Gedda, MR; Mudavath, SL; Parvez, S; Singh, A; Singh, OP; Sundar, S; Verma, A; Yadagiri, G	1
Alcoba, G; Alvar, J; Alves, F; Dorlo, TPC; Egondi, T; Fikre, H; Ismail Omer Haroun, A; Khalil, EAG; Mbui, J; Mekonnen, T; Mersha, D; Mohammed, R; Musa Younis, B; Musa, AM; Muthoni Ouattara, G; Nakanwagi, P; Njenga, S; Nour, A; Olobo, J; Omollo, T; Ritmeijer, K; Sagaki, P; Sisay, K; Solomos, A; Taha Ahmed Elmukashfi, E; Verrest, L; Wasunna, M	1
Alves, F; Chu, WY; Dorlo, TPC; Huitema, ADR; Mbui, J; Mohammed, R; Musa, AM; Njenga, S; Olobo, J; Ritmeijer, K; Roseboom, IC; Solomos, A; Verrest, L; Wasunna, M	1

Reviews

17 review(s) available for phosphorylcholine and paromomycin

Article	Year
Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2000, Volume: 4, Issue:3 Topics: Adult; Amphotericin B; Animals; Antimony; Antiprotozoal Agents; Child; Humans; Leishmania donovani; Leishmaniasis, Visceral; Mice; Paromomycin; Phosphorylcholine; Treatment Outcome	2000
Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. The Lancet. Infectious diseases, 2002, Volume: 2, Issue:8 Topics: Aminoquinolines; Animals; Antiprotozoal Agents; Asia, Western; Brazil; Developing Countries; Dogs; Female; Humans; Leishmaniasis, Visceral; Male; Paromomycin; Phosphorylcholine; Sudan	2002
Current treatment approaches to leishmaniasis. Current opinion in infectious diseases, 2003, Volume: 16, Issue:5 Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Clinical Trials as Topic; Fluconazole; Humans; Leishmaniasis; Paromomycin; Pentamidine; Phosphorylcholine	2003
Cutaneous leishmaniasis: current and future management. Expert review of anti-infective therapy, 2003, Volume: 1, Issue:4 Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Humans; Immunotherapy; Leishmania; Leishmaniasis, Cutaneous; Paromomycin; Phosphorylcholine	2003
Progress in the treatment of a neglected infectious disease: visceral leishmaniasis. Expert review of anti-infective therapy, 2004, Volume: 2, Issue:2 Topics: Amphotericin B; Antimony; Antiprotozoal Agents; Clinical Trials as Topic; Deoxycholic Acid; Drug Combinations; Drug Costs; Humans; Leishmaniasis, Visceral; Paromomycin; Phosphatidylcholines; Phosphatidylglycerols; Phosphorylcholine; Practice Guidelines as Topic	2004
Clinical status of agents being developed for leishmaniasis. Expert opinion on investigational drugs, 2005, Volume: 14, Issue:11 Topics: Aminoquinolines; Antiprotozoal Agents; Fluconazole; Humans; Imiquimod; Ketoconazole; Leishmaniasis; Paromomycin; Phosphorylcholine	2005
Current scenario of drug development for leishmaniasis. The Indian journal of medical research, 2006, Volume: 123, Issue:3 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Design; Humans; Leishmania; Leishmaniasis; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Models, Chemical; Paromomycin; Phosphorylcholine	2006
Cutaneous leishmaniasis treatment. Travel medicine and infectious disease, 2007, Volume: 5, Issue:3 Topics: Administration, Cutaneous; Administration, Oral; Aminoquinolines; Amphotericin B; Animals; Antimony; Antiprotozoal Agents; Humans; Imiquimod; Injections, Intralesional; Injections, Intramuscular; Leishmaniasis, Cutaneous; Paromomycin; Pentamidine; Phosphorylcholine	2007
Drug combinations for visceral leishmaniasis. Current opinion in infectious diseases, 2010, Volume: 23, Issue:6 Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Cost-Benefit Analysis; Drug Resistance; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Leishmaniasis, Visceral; Paromomycin; Phosphorylcholine	2010
Visceral leishmaniasis: elimination with existing interventions. The Lancet. Infectious diseases, 2011, Volume: 11, Issue:4 Topics: Amphotericin B; Antiprotozoal Agents; Communicable Disease Control; Drug Therapy, Combination; Humans; Leishmaniasis, Visceral; Paromomycin; Phosphorylcholine	2011
Leishmaniasis: current status of available drugs and new potential drug targets. Asian Pacific journal of tropical medicine, 2012, Volume: 5, Issue:6 Topics: Aminoquinolines; Amphotericin B; Antigens, Protozoan; Antimony Sodium Gluconate; Antiprotozoal Agents; Caspase Inhibitors; Cyclin-Dependent Kinases; Drug Discovery; Enzyme Inhibitors; Folic Acid Antagonists; Humans; Leishmaniasis; Macrophages; Microbodies; Mitogen-Activated Protein Kinase Kinases; Paromomycin; Pentamidine; Phosphorylcholine; Polyamines; Protease Inhibitors; Sterols; Sulfhydryl Compounds; Topoisomerase Inhibitors	2012
Drug delivery systems for the topical treatment of cutaneous leishmaniasis. Expert opinion on drug delivery, 2012, Volume: 9, Issue:9 Topics: Administration, Cutaneous; Aminoquinolines; Amphotericin B; Animals; Antiprotozoal Agents; Drug Delivery Systems; Humans; Imiquimod; Leishmaniasis, Cutaneous; Naphthoquinones; Paromomycin; Phosphorylcholine; Skin Absorption	2012
Leishmaniasis: an update of current pharmacotherapy. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:1 Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Drug Therapy, Combination; Humans; Leishmania donovani; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Parasitic Sensitivity Tests; Paromomycin; Phosphorylcholine; Practice Guidelines as Topic; Species Specificity; Treatment Outcome	2013
Can a simple outpatient-based treatment be used to treat cutaneous leishmaniasis in young children? A Critically Appraised Topic. The British journal of dermatology, 2015, Volume: 172, Issue:4 Topics: Administration, Cutaneous; Ambulatory Care; Aminoglycosides; Antiprotozoal Agents; Child, Preschool; Humans; Leishmaniasis, Cutaneous; Male; Paromomycin; Phosphorylcholine; Randomized Controlled Trials as Topic	2015
Liposomal formulations in the pharmacological treatment of leishmaniasis: a review. Journal of liposome research, 2017, Volume: 27, Issue:3 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Compounding; Drug Delivery Systems; Drug Liberation; Humans; Leishmaniasis; Liposomes; Nanoparticles; Paromomycin; Particle Size; Pentamidine; Phosphorylcholine; Surface Properties	2017
Amphotericin B for treatment of visceral leishmaniasis: systematic review and meta-analysis of prospective comparative clinical studies including dose-ranging studies. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2018, Volume: 24, Issue:6 Topics: Amphotericin B; Antiprotozoal Agents; Clinical Trials as Topic; Deoxycholic Acid; Drug Combinations; Drug Compounding; Evidence-Based Medicine; Female; Humans; Leishmaniasis, Visceral; Male; Paromomycin; Phosphorylcholine; Survival Analysis; Treatment Outcome	2018
Chemotherapeutics of visceral leishmaniasis: present and future developments. Parasitology, 2018, Volume: 145, Issue:4 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Clinical Trials as Topic; Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; Humans; India; Leishmania donovani; Leishmaniasis, Visceral; Meglumine Antimoniate; Paromomycin; Phosphorylcholine; Psychodidae; Sheep; South America; Treatment Outcome	2018

Trials

7 trial(s) available for phosphorylcholine and paromomycin

Article	Year
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet (London, England), 2011, Feb-05, Volume: 377, Issue:9764 Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Child; Child, Preschool; Creatinine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemoglobins; Humans; India; Leishmaniasis, Visceral; Liver; Liver Function Tests; Male; Middle Aged; Paromomycin; Phosphorylcholine; Recurrence; Young Adult	2011
TLR9 and MyD88 are crucial for the maturation and activation of dendritic cells by paromomycin-miltefosine combination therapy in visceral leishmaniasis. British journal of pharmacology, 2014, Volume: 171, Issue:5 Topics: Adult; Antiprotozoal Agents; Cells, Cultured; Dendritic Cells; Drug Combinations; Female; HEK293 Cells; Humans; Interleukin-10; Interleukin-12; Leishmaniasis, Visceral; Male; Myeloid Differentiation Factor 88; Paromomycin; Phosphorylcholine; Toll-Like Receptor 9	2014
Safety and efficacy of a combination of paromomycin and miltefosine for two vs. three courses in patients with post-kala-azar dermal leishmaniasis: an observational pilot study. The British journal of dermatology, 2017, Volume: 177, Issue:2 Topics: Administration, Oral; Adult; Antiprotozoal Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Injections, Intramuscular; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Paromomycin; Phosphorylcholine; Pilot Projects; Treatment Outcome	2017
Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh. PLoS neglected tropical diseases, 2017, Volume: 11, Issue:5 Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Bangladesh; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Leishmaniasis, Visceral; Male; Middle Aged; Paromomycin; Phosphorylcholine; Recurrence; Treatment Outcome; Young Adult	2017
Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India. PLoS neglected tropical diseases, 2018, Volume: 12, Issue:10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Antiprotozoal Agents; Child; Child, Preschool; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; India; Leishmaniasis, Visceral; Male; Middle Aged; Paromomycin; Phosphorylcholine; Prospective Studies; Treatment Outcome; Young Adult	2018
Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 02-08, Volume: 76, Issue:3 Topics: Adult; Africa, Eastern; Antimony Sodium Gluconate; Antiprotozoal Agents; Child; Drug Therapy, Combination; Humans; Leishmaniasis, Visceral; Paromomycin; Phosphorylcholine; Treatment Outcome	2023
Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis. The Journal of antimicrobial chemotherapy, 2023, 11-06, Volume: 78, Issue:11 Topics: Adult; Antiprotozoal Agents; Child; Humans; Kenya; Leishmaniasis, Visceral; Paromomycin; Phosphorylcholine; Treatment Outcome; Uganda	2023

Other Studies

36 other study(ies) available for phosphorylcholine and paromomycin

Article	Year
Drug resistance in Indian visceral leishmaniasis. Tropical medicine & international health : TM & IH, 2001, Volume: 6, Issue:11 Topics: Aminoquinolines; Amphotericin B; Antimony; Antiprotozoal Agents; Dose-Response Relationship, Drug; Drug Resistance; Geography; History, 20th Century; History, 21st Century; Humans; India; Leishmaniasis, Visceral; Paromomycin; Pentamidine; Phosphorylcholine; Treatment Outcome	2001
The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis. Antimicrobial agents and chemotherapy, 2003, Volume: 47, Issue:5 Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Buthionine Sulfoximine; Drug Resistance; Female; Glutathione; Leishmania donovani; Leishmaniasis, Visceral; Male; Mice; Mice, Inbred BALB C; Paromomycin; Phosphorylcholine	2003
Leishmaniasis. Nature reviews. Microbiology, 2004, Volume: 2, Issue:9 Topics: Animals; Antiprotozoal Agents; Humans; Insect Control; Leishmania; Leishmaniasis; Paromomycin; Phosphorylcholine; Protozoan Vaccines	2004
Challenges in the management of visceral leishmaniasis. Indian pediatrics, 2005, Volume: 42, Issue:6 Topics: Amebicides; Amphotericin B; Antimony Sodium Gluconate; Antiparasitic Agents; Antiprotozoal Agents; Enzyme-Linked Immunosorbent Assay; Fluorescent Antibody Technique, Indirect; Humans; Immunoglobulin G; Leishmaniasis, Visceral; Paromomycin; Pentamidine; Phosphorylcholine	2005
Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs. Parasitology research, 2007, Volume: 101, Issue:5 Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Drug Resistance; Humans; Iran; Leishmania tropica; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Parasitic Sensitivity Tests; Paromomycin; Phosphorylcholine	2007
Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India. Tropical medicine & international health : TM & IH, 2009, Volume: 14, Issue:1 Topics: Adolescent; Adult; Age Distribution; Aged; Amphotericin B; Anthropometry; Antiprotozoal Agents; Body Weight; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Costs; Female; Humans; India; Infant; Leishmaniasis, Visceral; Liposomes; Male; Middle Aged; Paromomycin; Phosphorylcholine; Sex Distribution	2009
Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India. Tropical medicine & international health : TM & IH, 2009, Volume: 14, Issue:8 Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Child; Cost-Benefit Analysis; Direct Service Costs; Drug Administration Schedule; Drug Costs; Female; Hospital Costs; Humans; India; Leishmaniasis, Visceral; Male; Paromomycin; Phosphorylcholine; Practice Guidelines as Topic; Young Adult	2009
Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens. The Journal of antimicrobial chemotherapy, 2009, Volume: 64, Issue:6 Topics: Administration, Oral; Administration, Topical; Animals; Disease Models, Animal; Drug Therapy, Combination; Female; Leishmania major; Leishmaniasis, Cutaneous; Mice; Mice, Inbred BALB C; Paromomycin; Phosphorylcholine; Skin; Spleen; Treatment Outcome	2009
Selection and phenotype characterization of potassium antimony tartrate-resistant populations of four New World Leishmania species. Parasitology research, 2010, Volume: 107, Issue:1 Topics: Amphotericin B; Animals; Antimony Potassium Tartrate; Antiprotozoal Agents; Culture Media; Drug Resistance; Inhibitory Concentration 50; Leishmania; Leishmaniasis; Liver; Mice; Mice, Inbred C57BL; Mice, Knockout; Paromomycin; Phenotype; Phosphorylcholine; Selection, Genetic; Serial Passage; Spleen; Virulence	2010
Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. The American journal of tropical medicine and hygiene, 2010, Volume: 83, Issue:1 Topics: AIDS-Related Opportunistic Infections; HIV; HIV Infections; HIV-1; Humans; Itraconazole; Leishmaniasis; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Opportunistic Infections; Parasitic Sensitivity Tests; Paromomycin; Phosphorylcholine; Recurrence; Treatment Failure	2010
Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:11 Topics: Administration, Oral; Administration, Topical; Animals; Anti-Bacterial Agents; Antiprotozoal Agents; Female; Leishmania; Leishmaniasis; Mice; Mice, Inbred BALB C; Paromomycin; Phosphorylcholine; Skin	2010
Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. PLoS neglected tropical diseases, 2010, Sep-07, Volume: 4, Issue:9 Topics: Amphotericin B; Antiprotozoal Agents; Bangladesh; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; India; Leishmaniasis, Visceral; Models, Statistical; Nepal; Paromomycin; Phosphorylcholine	2010
Immunomodulatory effect of picroliv on the efficacy of paromomycin and miltefosine in combination in experimental visceral leishmaniasis. Experimental parasitology, 2011, Volume: 127, Issue:2 Topics: Animals; Antiprotozoal Agents; Cell Proliferation; Cinnamates; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycosides; Leishmania donovani; Leishmaniasis, Visceral; Lymphocytes; Male; Mesocricetus; Paromomycin; Phagocytosis; Phosphorylcholine; Random Allocation; Reactive Nitrogen Species; Reactive Oxygen Species; Vanillic Acid	2011
Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India. Future microbiology, 2010, Volume: 5, Issue:9 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Therapy, Combination; Humans; India; Leishmania donovani; Leishmaniasis, Visceral; Paromomycin; Phosphorylcholine; Treatment Outcome	2010
Combination therapy for visceral leishmaniasis. Lancet (London, England), 2011, Feb-05, Volume: 377, Issue:9764 Topics: Amphotericin B; Antiprotozoal Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; India; Leishmaniasis, Visceral; Paromomycin; Phosphorylcholine; Randomized Controlled Trials as Topic	2011
Tolerance to drug-induced cell death favours the acquisition of multidrug resistance in Leishmania. Cell death & disease, 2011, Sep-01, Volume: 2 Topics: Amphotericin B; Antimony; Antiprotozoal Agents; Apoptosis; Cell Death; Drug Resistance, Multiple; Drug Tolerance; Leishmania infantum; Methotrexate; Paromomycin; Phosphorylcholine; Reactive Oxygen Species	2011
Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. PLoS neglected tropical diseases, 2012, Volume: 6, Issue:5 Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Child; Female; Humans; India; Inhibitory Concentration 50; Leishmania donovani; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Macrophages; Male; Middle Aged; Parasitic Sensitivity Tests; Paromomycin; Phosphorylcholine; Young Adult	2012
Combination of paromomycin and miltefosine promotes TLR4-dependent induction of antileishmanial immune response in vitro. The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:10 Topics: Adolescent; Adult; Antiprotozoal Agents; Artificial Gene Fusion; Cell Survival; Cells, Cultured; Female; Gene Expression Profiling; Genes, Reporter; Humans; Immunologic Factors; Leishmania donovani; Luciferases; Macrophages; Male; NF-kappa B; Nitric Oxide; Paromomycin; Phosphorylcholine; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha; Young Adult	2012
Susceptibility of clinical isolates of Leishmania aethiopica to miltefosine, paromomycin, amphotericin B and sodium stibogluconate using amastigote-macrophage in vitro model. Experimental parasitology, 2013, Volume: 134, Issue:1 Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Cells, Cultured; Ethiopia; Humans; Inhibitory Concentration 50; Leishmania; Leishmaniasis, Cutaneous; Macrophages, Peritoneal; Mice; Parasitic Sensitivity Tests; Paromomycin; Phosphorylcholine	2013
Comment on: leishmaniasis: an update of current pharmacotherapy. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:9 Topics: Amphotericin B; Antiprotozoal Agents; Humans; Leishmaniasis, Visceral; Organometallic Compounds; Paromomycin; Phosphorylcholine	2013
Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum. Parasitology research, 2014, Volume: 113, Issue:5 Topics: Animals; Antimony; Antiprotozoal Agents; Drug Resistance; Female; Humans; Leishmania donovani; Macrophages; Mice; Parasitic Sensitivity Tests; Paromomycin; Phosphorylcholine	2014
In Vivo Selection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:8 Topics: Animals; Antiprotozoal Agents; Cricetinae; Disease Models, Animal; Drug Resistance; Female; Leishmania donovani; Leishmania infantum; Leishmaniasis, Visceral; Parasitic Sensitivity Tests; Paromomycin; Phosphorylcholine	2015
Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis. The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:12 Topics: Administration, Oral; Administration, Topical; Animals; Antiprotozoal Agents; Appointments and Schedules; Disease Models, Animal; Drug Therapy, Combination; Injections, Intramuscular; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Mesocricetus; Organometallic Compounds; Paromomycin; Phosphorylcholine; Skin; Spleen; Treatment Outcome	2015
Evidence of a drug-specific impact of experimentally selected paromomycin and miltefosine resistance on parasite fitness in Leishmania infantum. The Journal of antimicrobial chemotherapy, 2016, Volume: 71, Issue:7 Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Resistance; Female; Humans; Leishmania infantum; Leishmaniasis, Visceral; Mice, Inbred BALB C; Paromomycin; Phosphorylcholine; Selection, Genetic; Virulence	2016
Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum. PLoS neglected tropical diseases, 2017, Volume: 11, Issue:5 Topics: Animals; Antiprotozoal Agents; Cricetinae; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Leishmania infantum; Leishmaniasis, Visceral; Mice; Paromomycin; Phosphorylcholine	2017
Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis. Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:8 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Chloroquine; Disease Models, Animal; Drug Combinations; Female; Leishmania major; Leishmania mexicana; Leishmaniasis, Cutaneous; Mice; Mice, Inbred BALB C; Parasite Load; Parasitic Sensitivity Tests; Paromomycin; Phosphorylcholine	2017
Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy. BMC infectious diseases, 2017, 07-07, Volume: 17, Issue:1 Topics: Amphotericin B; Antiprotozoal Agents; Biopsy; Female; Humans; Immunocompromised Host; Leishmania; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Macrophages; Middle Aged; Paromomycin; Phosphorylcholine; Polymerase Chain Reaction; Recurrence	2017
Genomic and transcriptomic alterations in Leishmania donovani lines experimentally resistant to antileishmanial drugs. International journal for parasitology. Drugs and drug resistance, 2018, Volume: 8, Issue:2 Topics: Antimony; Antiprotozoal Agents; Drug Resistance, Multiple; Genomics; Leishmania donovani; Leishmania infantum; Leishmania major; Multidrug Resistance-Associated Proteins; Parasitic Sensitivity Tests; Paromomycin; Phenotype; Phosphorylcholine; Transcriptome	2018
Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme. Infectious diseases of poverty, 2018, Aug-13, Volume: 7, Issue:1 Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Amphotericin B; Antiprotozoal Agents; Bangladesh; Female; Humans; Leishmania donovani; Leishmania tropica; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Middle Aged; Myocardial Infarction; Paromomycin; Patient Safety; Pharmacovigilance; Phosphorylcholine; Quality of Life; Recurrence; Survival Analysis	2018
Impact of primary mouse macrophage cell types on Leishmania infection and in vitro drug susceptibility. Parasitology research, 2018, Volume: 117, Issue:11 Topics: Amphotericin B; Animals; Antimony; Antiprotozoal Agents; Cells, Cultured; Drug Resistance; Female; Interleukin-6; Leishmania infantum; Leishmaniasis; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Nitric Oxide; Parasitic Sensitivity Tests; Paromomycin; Phosphorylcholine; Reactive Oxygen Species; Tumor Necrosis Factor-alpha	2018
Eliminating visceral leishmaniasis in South Asia: the road ahead. BMJ (Clinical research ed.), 2019, Jan-22, Volume: 364 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Bangladesh; Disease Vectors; Drug Therapy, Combination; Epidemiological Monitoring; Humans; India; International Cooperation; Leishmaniasis, Visceral; Neglected Diseases; Nepal; Paromomycin; Phosphorylcholine; Program Development; Program Evaluation	2019
Chemogenomic Profiling of Antileishmanial Efficacy and Resistance in the Related Kinetoplastid Parasite Trypanosoma brucei. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:8 Topics: Adenosine Triphosphatases; Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Leishmania; Paromomycin; Phosphorylcholine; R-SNARE Proteins; Trypanosoma brucei brucei	2019
Field effectiveness of new visceral leishmaniasis regimens after 1 year following treatment within public health facilities in Bihar, India. PLoS neglected tropical diseases, 2019, Volume: 13, Issue:9 Topics: Adolescent; Amphotericin B; Antiprotozoal Agents; Child; Child, Preschool; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; India; Leishmaniasis, Visceral; Male; Paromomycin; Phosphorylcholine; Recurrence; Treatment Outcome	2019
Coupling chemical mutagenesis to next generation sequencing for the identification of drug resistance mutations in Leishmania. Nature communications, 2019, 12-09, Volume: 10, Issue:1 Topics: Drug Resistance; High-Throughput Nucleotide Sequencing; Leishmania; Mutagenesis; Mutation; Paromomycin; Phosphorylation; Phosphorylcholine	2019
Comparison of Turkiye parazitolojii dergisi, 2020, Mar-20, Volume: 44, Issue:1 Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Drug Resistance; Female; Genotyping Techniques; Humans; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Paromomycin; Phosphorylcholine; Real-Time Polymerase Chain Reaction; Turkey	2020
Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis. Scientific reports, 2020, 07-22, Volume: 10, Issue:1 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Cell Line; Emulsions; Leishmania donovani; Leishmaniasis, Visceral; Lipids; Male; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Nanoparticles; Paromomycin; Particle Size; Phosphorylcholine	2020